{"entity":{"id":"idea-tr1-representativeness-in-the-label","kind":"idea","name":"Print the participation-to-prevalence ratio in every drug label and assessment report","aka":[],"tldr":"A drug's label should say plainly how well the people in its trials matched the people who get the disease: 'Black patients were 4 percent of participants and 22 percent of cases.' Doctors and patients can then judge how far to trust the result.","summary":"Labels and public assessment reports (FDA, EMA EPAR) include a standard representativeness panel: enrolled percentages by race, ethnicity, sex, age band and region beside incidence-based expected percentages, with a participation-to-prevalence ratio per stratum. The panel is machine-readable and aggregated in a public dashboard.","asOf":"2026-09-08","links":[{"label":"FDA Drug Trials Snapshots","url":"https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots"}],"tags":[],"related":["fda-approvals"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-trial-diversity","b-knowledge-diffusion"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A visible ratio in the label will increase sponsor effort on representativeness and will be used by guideline committees and payers when weighing evidence for under-represented groups.","rationale":"FDA Drug Trials Snapshots already publish demographics, but separately from the label; placing the comparison in the document clinicians read makes the gap salient at prescribing.","test":"Survey clinician and guideline-committee use of the panel after introduction; track change in ratios across approvals over five years.","maturity":"speculative","actor":"regulator","cost":"small","horizonYears":1},"route":"/ideas/idea-tr1-representativeness-in-the-label/","neighbours":{"collection":[{"id":"fda-approvals","kind":"collection","name":"FDA Oncology Approvals (OCE) & Novel Drug Approvals","route":"/collections/fda-approvals/"}],"bottleneck":[{"id":"b-knowledge-diffusion","kind":"bottleneck","name":"Knowledge reaches practice too slowly","route":"/bottlenecks/b-knowledge-diffusion/"},{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/"}]}}